Indeed, the clinical phase II trial with trimodulin (CIGMA trial) confirmed that in the patients with sCAP, the IgM levels were significantly reduced and that those patients in particular benefited from trimodulin treatment as shown by a reduced 28-day mortality rate compared to the placebo group [44]. The gene discussed is CD40LG; the disease is syringocystadenoma papilliferum.